A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)
Non-small Cell Lung Cancer (NSCLC)
Esophageal Cancer
Gastric Cancer
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Breast Cancer
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Prostate Cancer
Urothelial Carcinoma
Neuroendocrine Tumor (NET)
Neuroendocrine Carcinoma (NEC)
Soft Tissue Sarcoma
Nuclear Protein in Testis (NUT) Carcinoma

Interventions

DRUG: MT-4561

Sponsor

Tanabe Pharma America, Inc.